Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice | Zendy

Ann Sturdy | Zendy; Anna L. Goodman | Zendy; Ricardo J. José | Zendy; Angela Loyse | Zendy; M. O'Donoghue | Zendy; Onn Min Kon | Zendy; Martin Dedicoat | Zendy; Thomas S. Harrison | Zendy; Laurence John | Zendy; Marc Lipman | Zendy; Graham Cooke | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice

Author(s) -

Ann Sturdy,

Anna L. Goodman,

Ricardo J. José,

Angela Loyse,

M. O'Donoghue,

Onn Min Kon,

Martin Dedicoat,

Thomas S. Harrison,

Laurence John,

Marc Lipman,

Graham Cooke

Publication year - 2011

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkr221

Subject(s) - ototoxicity , capreomycin , medicine , amikacin , tuberculosis , intensive care medicine , pediatrics , surgery , antibiotics , mycobacterium tuberculosis , chemotherapy , ethambutol , pathology , microbiology and biotechnology , cisplatin , biology

Multidrug-resistant tuberculosis (MDR-TB) is an increasing challenge to health services globally. Although new drugs are in development, current guidelines still recommend prolonged use of injectable antimicrobials (usually amikacin, kanamycin or capreomycin). The evidence base to inform treatment and monitoring strategies is very limited.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research